Clopiodgrel-01 (Clopidogrel Tablets Usp Apotex 1)
Clopidogrel
Product Images NDC 70882-116
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 70882-116). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Cambridge Therapeutics Technologies, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure8.jpg (Clopidogrel Tablets Usp Apotex 10)
Clopidogrel Tablets, Usp 75mg (Clopidogrel Tablets Usp Apotex 11)
Figure-01 (Clopidogrel Tablets Usp Apotex 2)
The text describes a figure (Figure 1) that shows the exposure to Clopidogrel Active Metabolite after taking Clopidogrel 75mg alone or with Proton Pump Inhibitors (PPIs). The figure shows the mean and 90% confidence interval of the effect of different PPIs on active metabolite AUC. The PPIs listed are Dextansoprazole, Lansoprazole, Pastoprazole, and Omeprazole. The figure also shows the change relative to taking Clopidogrel administered alone.*
Figure2 (Clopidogrel Tablets Usp Apotex 3)
The text provides a figure that shows the cumulative event rate of cardiovascular death, myocardial infarction, and stroke in the CURE Study. It compares the effect of placebo (with aspirin) to clopidogrel (with aspirin) over a follow-up of several months, and reports a significant difference between the two treatments in terms of efficacy. Other standard therapies were also used in the study.*
Figure3.jpg (Clopidogrel Tablets Usp Apotex 4)
Figure3b.jpg (Clopidogrel Tablets Usp Apotex 5)
The text provided is a table showing data related to the CURE study. It includes information such as subgroup, the number of patients, the percentage of patients receiving certain medications or interventions, and the hazard ratio for each characteristic. The data seems to be related to the comparison of the efficacy of clopidogrel versus placebo for certain patient characteristics.*
Figure4 (Clopidogrel Tablets Usp Apotex 6)
Cumulative event rates for death in the COMMIT study are shown in Figure 4. The data compares the percentage of deaths that occurred before and after a treatment intervention, which resulted in a proportional reduction (p-033) in deaths. Only reported patients were included in the data analysis.*
Figure5 (Clopidogrel Tablets Usp Apotex 7)
Figure 5 shows the cumulative event rates for the combined endpoint of re-infarction, stroke or death in the COMMIT study. The placebo group had 2310 events (10.1%), while the group treated with clopidogrel had 2121 events (8.2%). The proportionate risk reduction was 9%, with a confidence interval of 5-0.002. The events of re-infarction or stroke occurred early, within 5-7 days of randomization. All patients received aspirin.*
Figure6.jpg (Clopidogrel Tablets Usp Apotex 8)
The text is describing the effects of adding Clopidogrel to Aspirin on the combined primary endpoint across baseline and concomitant medication subgroups for the COMMIT Study. It includes data on subgroups such as Gender, Heart Rate, and Fibrinolytic Agent Given, and the number and percentage of participants who received Clopidogrel. The text also includes odds ratios for the overall primary endpoint, as well as data on placebo and Clopidogrel groups.*
Figure7.jpg (Clopidogrel Tablets Usp Apotex 9)
The figure shows the incidence of fatal or non-fatal vascular events in the CAPRIE Study. The cumulative event rate is presented in percentages over months of follow-up. Clopidogrel was found to have a significant reduction in vascular events compared to the control group. The data is presented graphically with no additional information available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
